Patient-Centric Integrated Virtual Healthcare Company in Production

Grand Rounds and Doctor On Demand merge to revolutionize how millions of Americans receive healthcare in a first of its kind patient-centric virtual care organization.

A first of its kind integrated virtual care company is in the works through the collaboration of Grand Rounds, a leader in healthcare quality and navigation, and Doctor On Demand, the nation’s leading virtual care provider.

These two healthcare platforms will offer a full suite of digital and interactive solutions to help people address the $300 billion problem of uncoordinated care in the U.S., according to a release.

The new company will include a combination of Grand Rounds’ data-driven clinical navigation platform and patient advocacy tools with Doctor On Demand’s preeminent virtual care offering to provide an unparalleled member experience. It will accelerate the adoption of virtual care in key areas including primary care, specialty care, chronic condition management, and behavioral health.

Owen Tripp, CEO of Grand Rounds, will serve as the CEO of the expanded business. Both companies will continue to operate under their existing brands for the time being, the release said.

“No one has done this before, combining navigation and virtual care delivery," Tripp said. "We think it’s the future. People make unguided healthcare decisions every day, often with higher costs and worse outcomes. Now, with Doctor On Demand, we’ll offer them coordinated support on all fronts—physical, behavioral, financial, administrative—and we’ll do it for everything from acute issues to life-long health. This is truly complete care, and it’s what we all need.”

Hill Ferguson, CEO of Doctor On Demand, said the collaboration creates a next-generation virtual care company with a nationwide practice of diverse, dedicated providers and a multidisciplinary care team.

“By fully integrating medical and behavioral healthcare with clinical navigation, we’re impacting healthcare where it actually happens—between a patient and their provider—and ensuring that experience is seamless, personalized, and can follow the patient wherever they go,” Ferguson said.

The transaction is subject to regulatory approval and customary closing conditions and is expected to close in the first half of 2021. Terms of the transaction were not disclosed.

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.